Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.

Oncotarget - 20 Oct 2015

Curi Dany A, Beauchamp Elspeth M, Blyth Gavin T, Arslan Ahmet Dirim, Donato Nicholas J, Giles Francis J, Altman Jessica K, Platanias Leonidas C

Abstract excerpt

We investigated the efficacy of targeting the PIM kinase pathway in Philadelphia chromosome-positive (Ph+) leukemias. We provide evidence that inhibition of PIM, with the pan-PIM inhibitor SGI-1776, results in suppression of classic PIM effectors and also elements of the mTOR pathway, suggesting interplay between PIM and mTOR signals. Our data demonstrate that PIM inhibition enhances the effects of imatinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Genes, abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Imidazoles

Share to K562 Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Philadelphia Chromosome

Share to Pyridazines

Source

Open in PubMed Open full text

Identifiers

PMID: 26375673
DOI: 10.18632/oncotarget.5091
PMCID: PMC4741759

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.PMID 26375673Read ↗

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.Semantic proximity Read ↗

The PIM kinases in hematological cancersSemantic proximity Read ↗

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read ↗

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Semantic proximity Read ↗

Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeuticsSemantic proximity Read ↗

The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPNSemantic proximity Read ↗

Targeting PIM Kinases to Overcome Therapeutic Resistance in CancerSemantic proximity Read ↗

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsSemantic proximity Read ↗

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.Semantic proximity Read ↗

Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABLSemantic proximity Read ↗

Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase InhibitorsSemantic proximity Read ↗

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.